September 9, 2011
In a director notification issued on September 8, the Pharmaceutical and Food Safety Bureau's (PFSB) Evaluation and Licensing Division informed prefectures of the designation of six pharmaceutical products, including ruxolitinib from Novartis Pharma, as orphan drugs. The proposed indication or...read more